Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11382985 Anti-tumour immune responses to modified self-epitopes

Patent 11382985 was granted and assigned to Scancell on July, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Linda Gillian Durrant0

Rachel Louise Metheringham0

Victoria Anne Brentville0

Date of Patent

July 12, 2022

Patent Application Number

16823814

Date Filed

March 19, 2020

Patent Citations

US Patent 10233220 Anti-tumour response to modified self-epitopes

0

Patent Primary Examiner

CPC Code

The present invention relates to modified citrullinated enolase peptides that can be used as targets for cancer immunotherapy. These peptides can be used as vaccines or as targets for monoclonal antibody (mAb) therapy. Such vaccines cur mAbs may be used in the treatment of cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11382985 Anti-tumour immune responses to modified self-epitopes

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.